Lyra Therapeutics Inc. Annual cash flow by MarketWatch. View LYRA net cash flow, operating cash flow, operating expenses and cash dividends.
Investors might want to bet on Lyra Therapeutics, Inc. (LYRA), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings ...
WATERTOWN, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory ...
It’s unusual for a mental health care company to achieve unicorn status—let alone a $2 billion-plus valuation. But Lyra Health has raised $187 million in funding, garnering it a $2.3 billion valuation ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback